This document has been posted in compliance with the FOIA Improvement Act of 2016, which requires agencies to make certain records that have been requested three or more times publicly available. It provides a snapshot of CTP's internal thinking on certain aspects of tobacco regulatory science. The information it contains is subject to change, such as based on changes in policy, the regulatory framework, or regulatory science. It is not binding on FDA or the public. It may have been withdrawn or superseded after it was issued or may otherwise be outdated. FDA's review of tobacco product applications is based on the specific facts presented in each application, and is documented in reviews particular to each application.

Given the above, you should not use this document as a tool, guide, or manual for the preparation of applications or submissions to FDA. Instead, all interested persons should refer to the Federal Food, Drug, and Cosmetic Act, and its implementing regulations, as well as guidance documents prepared by FDA, for information on FDA's tobacco authorities and regulatory framework. FDA <u>also regularly posts</u> <u>additional resources</u> for applicants, such as webinars and application tips, on <u>CTP's website</u> and <u>social media</u>.

Memorandum

То:	File		
From:	Anne Radway, M.S.Anne M.Digitally signed by Anne M. Radway -SDivision of Regulatory Project ManagementRadway -SDate: 2021.06.29 17:02:25 -04'00'		
Through:	Matthew Holman, Ph.D. Director Office of Science	Digitally signed by Matthew R. Holman -S Date: 2021.06.30 08:27:30 -04'00'	
Subject:	Updated Prioritization of PMTA ¹ Filing Reviews		

Background

In general, the prioritization process used to select and review PMTAs submitted as of September 9, 2020, follows the randomization order previously outlined in the August 31, 2020, memorandum. This current memo seeks to clarify the selection of certain PMTAs for Filing review.

Discussion

We have now identified all of the PMTAs included in marketing application submissions submitted by September 9, 2020. Based on this information, we determined that a small number of companies submitted such a large number of PMTAs that they, collectively, represent the vast majority of all PMTAs submitted by September 9, 2020. In order to complete as many Filing reviews as possible by September 9, 2021, we are going to change our prioritization of work such that the PMTAs in Table 1 become the top priority for Filing review. The prioritization of these applicant's PMTAs will be based on the number of individual products submitted by a single company (as listed in Table 1) such that the company with the most PMTAs will be reviewed first, then the company with the second most PMTAs will be reviewed, etc. Based on the six filing teams available to conduct reviews, the top 12 applicants were pulled out and moved to the top of priority list so that each team has two of the bundles listed below.

¹ Premarket Tobacco Product Applications

STN	Company	Number of PMTAs
PM0002768	JD Nova Group LLC	4,682,920
PM0003607	Big Time Vapes	171,946
PM0001260	Perfect Vape LLC	140,198
PM0003566	Matrix Minds LLC	336,271
PM0003724	Imperial Vapors LLC	84,716
PM0002084	My Vape Bar LLC	66,174
PM0003720	Gothic Vapor LLC	61,723
PM0003726	Great American Vapes LLC	51,609
PM0003792	SWT Global Supply Inc.	47,687
PM0001968	Vapor Salon	47,108
(b) (4)	(b) (4)	42,352
PM0003571	Wall 2 Wall Vape	42,177

Table 1. Top Priority PMTAs for Filing Review